Why Is Cancer Focused Microcap Stock AIM ImmunoTech Trading Higher Today?
Portfolio Pulse from Vandana Singh
AIM ImmunoTech Inc announced that Roswell Park Comprehensive Cancer Center has reported positive topline data from its Phase 1 study evaluating Ampligen as a treatment for early-stage triple-negative breast cancer. The results confirmed that the treatment was well tolerated and showed promising clinical activity. A Phase 2 study is planned to determine if Ampligen may be a safe and effective alternative to pembrolizumab or pembrolizumab/NAC. Following the announcement, AIM shares are up 6.26% at $0.62.
September 11, 2023 | 5:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AIM ImmunoTech's positive Phase 1 study results for Ampligen in treating early-stage triple-negative breast cancer have led to a 6.26% increase in its stock price.
The positive results from the Phase 1 study of Ampligen, a drug developed by AIM ImmunoTech, have increased investor confidence in the company's potential, leading to a rise in its stock price. The announcement of a planned Phase 2 study further supports the potential for Ampligen to become a viable treatment option for early-stage triple-negative breast cancer, which could significantly boost the company's revenues in the future.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100